Loxoprofen Sodium Patch Receives Drug Registration Certificate
August 10, 2026
Source: drugdu
33
Fuyuan Pharmaceutical(601089.SH) announced that it has received a Drug Registration Certificate for Loxoprofen Sodium Patches from the National Medical Products Administration, approving the production of the drug. This drug is used for anti-inflammatory and analgesic purposes for osteoarthritis, muscle pain, and swelling or pain caused by trauma. As of the date of the announcement, the company's cumulative R&D investment in this drug is RMB 11.7065 million. Sales of Loxoprofen Sodium Patches in China's three major terminal markets and six major markets are projected to reach approximately RMB 901 million by 2025.
https://finance.eastmoney.com/a/202608073835312137.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap August 10, 2026
- Vonoprazan Fumarate Tablets Receive Drug Registration Certificate August 10, 2026
- Lenvatinib Mesylate Capsules Receive Drug Registration Certificate August 10, 2026
- Subsidiary obtains drug registration certificate for injectable multivitamins (12) August 10, 2026
- its stock price has shrunk by 90% from its issue price, and although it has finally received approval for its first product, the market landscape has already changed. August 4, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
